Company

Akouos, Inc.

Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.

All Programs Therapeutics Devices

Open filtered programs

Programs

linked to organization

Strong Evidence

1 status confirmed

Details Checked

0 open data checks

Company / Institution Links

3 / 0

industry vs non-industry records

Competitive Density

Pipeline Velocity

Completion Signal

Programs by Stage

Preclinical2

Phase 1/21

Trial / Program Status

Active1

Unknown2

Modality Mix

Gene Therapy3

Indication Coverage

Hearing Loss3

Genetic Hearing Loss2

Sensorineural Hearing Loss2

Vestibular Schwannoma1

Program Types

Therapeutic3

Population Tags

genetic2

pediatric2

adult1

congenital1

hearing-adjacent1

post-lingual1

pre-lingual1

unilateral1

vestibular-schwannoma1

Strong-Evidence Records

1 records

AK-antiVEGF by Eli Lilly and Akouos

Strong evidence

Gene TherapyPhase 1/2Active

AAVAnc80 vector-based therapeutic protein expression program designed to deliver anti-VEGF expression locally for unilateral vestibular schwannoma, with potential to preserve or improve hearing by modulating vestibular schwannoma biology.

Data checks: vestibular-schwannoma-hearing-adjacent

Checked Records With Caveats

3 checked · 0 open checks

GJB2 hearing loss gene therapy by Eli Lilly

Details checked

Gene TherapyPreclinicalUnknown

AAV-based inner-ear gene therapy intended to restore GJB2 expression in supporting cells for connexin 26-related hearing loss.

Data checks: current-status-not-publicly-disclosed, route-not-publicly-disclosed

AK-CLRN1 by Eli Lilly

Details checked

Gene TherapyPreclinicalUnknown

AAV-based inner-ear gene therapy intended to restore CLRN1 expression for Usher syndrome type 3A-associated hearing loss.

Data checks: current-status-not-publicly-disclosed, route-not-publicly-disclosed